Nuvectis Q2 2026: $115M Offering Closes, Ciprocopan Approved in China
NVCT has more than doubled off its 52-week low of $5.55.
Summary
Nuvectis reported Q2 2026 results, closed a $115 million follow-on offering, and announced the first marketing approval for ciprocopan in China. The offering extends cash runway into 2029, and multiple U.S. regulatory milestones are expected in Q4 2026.
Key Events · Earnings and Guidance · NVCT
-
$115M Follow-On Offering Closed
In July 2026, a public offering anchored by leading healthcare investors closed with $115 million in gross proceeds, including the overallotment. The raise extends the cash runway into the first half of 2029.
-
Ciprocopan Wins First Approval in China
Partner Haisco received marketing approval in China in July 2026 for ciprocopan (NXP100) in treatment-naive PNH, marking the first global approval of an oral, once-daily Complement Factor B inhibitor.
-
U.S. Regulatory Path Set for Q4 2026
A pre-IND meeting with the FDA, followed by an IND submission for ciprocopan, is expected in the fourth quarter of 2026. An IND submission for NXP200 is also anticipated in the same period.
-
Q2 2026 Financials: Cash $22.2M Pre-Offering
As of June 30, 2026, cash and equivalents stood at $22.2 million, prior to the $115 million raise. The net loss for the quarter was $7.0 million, up from $6.3 million a year ago.
Analysis · NVCT · Life Sciences
A transformative quarter for Nuvectis: the company closed a $115 million follow-on offering that pushes its cash runway into 2029, secured China's first approval for an oral Factor B inhibitor in PNH with ciprocopan, and mapped a clear U.S. regulatory path with IND submissions expected in Q4 2026. Anchored by healthcare specialists, the offering removes near-term financing risk and funds a broad development strategy. The China approval validates the drug's clinical profile and de-risks the global regulatory story. With a market cap near $680 million, the $115 million raise is substantial, and pipeline catalysts are now densely packed through year-end.
At the time of this filing, NVCT was trading at $21.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $681M. The 52-week trading range was $5.55 to $29.28. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.